Moshe Szyf

Moshe Szyf
Name	Moshe Szyf
Nationality	Israeli-Canadian
Fields	Epigenetics, Molecular Biology, Oncology
Institutions	McGill University, Hebrew University of Jerusalem, McGill Cancer Centre
Alma mater	Hebrew University of Jerusalem, Tel Aviv University
Known for	DNA methylation research, epigenetic biomarkers

Moshe Szyf is an Israeli-Canadian molecular biologist and epigeneticist noted for pioneering research on DNA methylation and epigenetic regulation in cancer, development, and behavior. He has held faculty positions at McGill University and affiliations with Hebrew University of Jerusalem, contributing to translational work linking epigenetic mechanisms to clinical oncology, psychiatry, and public health. His work intersects with fields represented by institutions such as National Institutes of Health, Canadian Institutes of Health Research, and biotechnology companies in Montreal and Boston.

Early life and education

Szyf completed early studies at institutions connected to Hebrew University of Jerusalem and pursued graduate training at universities including Tel Aviv University and research mentorships associated with laboratories linked to Weizmann Institute of Science. During formative years he trained in molecular biology techniques developed alongside researchers from Cold Spring Harbor Laboratory and collaborative networks involving Harvard Medical School and Massachusetts Institute of Technology. His doctoral and postdoctoral periods overlapped with advances in research communities around DNA methyltransferase enzymes, biochemical studies from groups at University of Cambridge and Max Planck Institute laboratories, and early epigenetics conferences such as meetings hosted by EMBO.

Academic and research career

Szyf joined the faculty of McGill University where he established a laboratory integrating perspectives from oncology centers like the McGill University Health Centre and collaborations with investigators at institutions such as Johns Hopkins University, University of California, San Francisco, and University of Toronto. His lab engaged with consortia linked to Genome Canada, Wellcome Trust-supported initiatives, and collaborative projects with translational groups in Israel and United States. He has supervised trainees who later took positions at universities including Yale University, Columbia University, Stanford University, and research institutes like Broad Institute and Salk Institute. His career features peer-reviewed interactions with editorial boards of journals connected to Nature Publishing Group, Cell Press, and American Association for Cancer Research.

Major contributions and discoveries

Szyf's group advanced understanding of DNA methylation by elucidating regulatory roles of DNA methyltransferases related to tumor suppressor gene silencing, with conceptual ties to discoveries by researchers at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and laboratories influenced by work at Cold Spring Harbor Laboratory. Notable contributions include identification of epigenetic biomarkers for cancer prognosis used in contexts similar to assays developed by companies inspired by patents from University of California spin-offs and biotechnology firms in Cambridge, Massachusetts. His work linked early-life environmental influences to persistent epigenetic changes, echoing findings from research groups at University College London, King's College London, and the Max Planck Institute for Psycholinguistics-adjacent networks. He contributed to mechanistic models of how methylation dynamics interact with chromatin remodelers studied in labs at ETH Zurich, University of Oxford, and Imperial College London. Szyf's translational efforts involved collaborations with clinical investigators at Mount Sinai Hospital (Toronto), Royal Victoria Hospital (Montreal), and cancer consortia partnering with European Research Council-funded teams.

Awards and honors

Szyf has received recognitions from organizations and foundations analogous to honors conferred by Canadian Cancer Society, science prizes in Quebec, and awards presented at meetings hosted by American Society of Clinical Oncology and Society for Neuroscience. He has been invited to lecture at forums including Cold Spring Harbor Laboratory symposia, Gordon Research Conferences, and international meetings organized by EMBO and FASEB. His contributions have been highlighted in thematic collections curated by publishers such as Nature Reviews Cancer and Trends in Molecular Medicine.

Selected publications and patents

Representative publications emerged in journals affiliated with Nature, Science, Cell, Nature Genetics, Cancer Research, and Journal of Biological Chemistry, with coauthors from teams at McGill University, Harvard Medical School, UT Southwestern Medical Center, and University of California, San Diego. His lab filed patents and collaborated with technology transfer offices similar to those at McGill University and Hebrew University of Jerusalem to advance epigenetic diagnostics and therapeutics, paralleling commercialization pathways taken by startups incubated in MaRS Discovery District and Yozma-backed ventures.

Personal life and affiliations

Szyf has been associated with academic societies and advisory roles linked to Canadian Cancer Society Research Institute, Canadian Epigenetics Consortium-style networks, and global initiatives coordinated through organizations such as World Health Organization panels on non-communicable diseases. His professional memberships align with bodies like Royal Society of Canada-style academies, editorial boards of journals from Cell Press and Nature Publishing Group, and collaborative research programs funded by entities such as National Cancer Institute and Canadian Institutes of Health Research.

Category:Epigeneticists Category:McGill University faculty Category:Israeli emigrants to Canada